AU2005296124A1 - Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor - Google Patents

Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor Download PDF

Info

Publication number: AU2005296124A1
Authority: AU; Australia
Prior art keywords: alkyl; compound; alkoxy; salt; haloc
Prior art date: 2004-10-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2005296124A

Other languages

English (en)

Inventor

Bertrand L. Chenard

Dario Doller

Manuka Ghosh

Alan J. Hutchison

Guiying Li

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Neurogen Corp

Original Assignee

Neurogen Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-13

Filing date

2005-10-04

Publication date

2006-04-27

2005-10-04 Application filed by Neurogen Corp filed Critical Neurogen Corp

2006-04-27 Publication of AU2005296124A1 publication Critical patent/AU2005296124A1/en

Status Abandoned legal-status Critical Current

Links

108010047068 Melanin-concentrating hormone receptor Proteins 0.000 title claims description 182
125000003118 aryl group Chemical group 0.000 title claims description 35
102000029828 Melanin-concentrating hormone receptor Human genes 0.000 title description 165
239000003446 ligand Substances 0.000 title description 10
DGGKXQQCVPAUEA-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octane Chemical class C1CCC2CCC1N2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 title description 9
150000001875 compounds Chemical class 0.000 claims description 266
125000000217 alkyl group Chemical group 0.000 claims description 118
-1 nitro, cyano, amino Chemical group 0.000 claims description 92
150000003839 salts Chemical class 0.000 claims description 86
125000003545 alkoxy group Chemical group 0.000 claims description 73
101800002739 Melanin-concentrating hormone Proteins 0.000 claims description 71
210000004027 cell Anatomy 0.000 claims description 69
229910052736 halogen Inorganic materials 0.000 claims description 67
150000002367 halogens Chemical class 0.000 claims description 66
125000000623 heterocyclic group Chemical group 0.000 claims description 65
230000027455 binding Effects 0.000 claims description 62
238000009739 binding Methods 0.000 claims description 60
238000000034 method Methods 0.000 claims description 60
238000003556 assay Methods 0.000 claims description 56
125000001424 substituent group Chemical group 0.000 claims description 56
230000000694 effects Effects 0.000 claims description 55
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 52
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 52
229910052739 hydrogen Inorganic materials 0.000 claims description 52
239000001257 hydrogen Substances 0.000 claims description 52
239000000203 mixture Substances 0.000 claims description 52
NMRPBPVERJPACX-UHFFFAOYSA-N octan-3-ol Chemical compound CCCCCC(O)CC NMRPBPVERJPACX-UHFFFAOYSA-N 0.000 claims description 46
125000004043 oxo group Chemical group O=* 0.000 claims description 42
125000000753 cycloalkyl group Chemical group 0.000 claims description 38
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 38
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 37
150000002431 hydrogen Chemical class 0.000 claims description 36
229910052757 nitrogen Inorganic materials 0.000 claims description 36
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 33
239000008194 pharmaceutical composition Substances 0.000 claims description 29
102000005962 receptors Human genes 0.000 claims description 29
108020003175 receptors Proteins 0.000 claims description 29
208000035475 disorder Diseases 0.000 claims description 28
238000000338 in vitro Methods 0.000 claims description 26
241001465754 Metazoa Species 0.000 claims description 25
201000010099 disease Diseases 0.000 claims description 20
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 19
238000011282 treatment Methods 0.000 claims description 19
125000004093 cyano group Chemical group *C#N 0.000 claims description 18
230000004913 activation Effects 0.000 claims description 17
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
241000282414 Homo sapiens Species 0.000 claims description 14
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 14
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
208000008589 Obesity Diseases 0.000 claims description 13
235000020824 obesity Nutrition 0.000 claims description 13
208000030814 Eating disease Diseases 0.000 claims description 12
208000019454 Feeding and Eating disease Diseases 0.000 claims description 12
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
235000014632 disordered eating Nutrition 0.000 claims description 11
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
210000000988 bone and bone Anatomy 0.000 claims description 10
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 10
230000001404 mediated effect Effects 0.000 claims description 10
125000005236 alkanoylamino group Chemical group 0.000 claims description 9
206010012601 diabetes mellitus Diseases 0.000 claims description 9
125000003226 pyrazolyl group Chemical group 0.000 claims description 9
125000004076 pyridyl group Chemical group 0.000 claims description 9
208000012201 sexual and gender identity disease Diseases 0.000 claims description 9
208000015891 sexual disease Diseases 0.000 claims description 9
208000019901 Anxiety disease Diseases 0.000 claims description 8
239000012530 fluid Substances 0.000 claims description 8
208000019622 heart disease Diseases 0.000 claims description 8
125000000714 pyrimidinyl group Chemical group 0.000 claims description 8
210000001519 tissue Anatomy 0.000 claims description 8
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 7
208000006011 Stroke Diseases 0.000 claims description 7
230000036506 anxiety Effects 0.000 claims description 7
125000000392 cycloalkenyl group Chemical group 0.000 claims description 7
125000002541 furyl group Chemical group 0.000 claims description 7
125000001072 heteroaryl group Chemical group 0.000 claims description 7
238000000670 ligand binding assay Methods 0.000 claims description 7
125000004193 piperazinyl group Chemical group 0.000 claims description 7
125000003386 piperidinyl group Chemical group 0.000 claims description 7
125000003373 pyrazinyl group Chemical group 0.000 claims description 7
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
125000000168 pyrrolyl group Chemical group 0.000 claims description 7
230000027425 release of sequestered calcium ion into cytosol Effects 0.000 claims description 7
125000001544 thienyl group Chemical group 0.000 claims description 7
125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 6
125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 6
125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 6
230000004075 alteration Effects 0.000 claims description 6
208000010877 cognitive disease Diseases 0.000 claims description 6
239000007788 liquid Substances 0.000 claims description 6
125000002757 morpholinyl group Chemical group 0.000 claims description 6
125000001624 naphthyl group Chemical group 0.000 claims description 6
125000004430 oxygen atom Chemical group O* 0.000 claims description 6
239000000546 pharmaceutical excipient Substances 0.000 claims description 6
239000000825 pharmaceutical preparation Substances 0.000 claims description 6
239000006188 syrup Substances 0.000 claims description 6
235000020357 syrup Nutrition 0.000 claims description 6
125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 6
125000004568 thiomorpholinyl group Chemical group 0.000 claims description 6
208000012639 Balance disease Diseases 0.000 claims description 5
208000001145 Metabolic Syndrome Diseases 0.000 claims description 5
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 5
239000002775 capsule Substances 0.000 claims description 5
230000001413 cellular effect Effects 0.000 claims description 5
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 5
125000002971 oxazolyl group Chemical group 0.000 claims description 5
125000000335 thiazolyl group Chemical group 0.000 claims description 5
125000001425 triazolyl group Chemical group 0.000 claims description 5
230000008859 change Effects 0.000 claims description 4
230000004634 feeding behavior Effects 0.000 claims description 4
125000001841 imino group Chemical group [H]N=* 0.000 claims description 4
125000003831 tetrazolyl group Chemical group 0.000 claims description 4
125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims description 3
239000000443 aerosol Substances 0.000 claims description 3
239000006071 cream Substances 0.000 claims description 3
238000002001 electrophysiology Methods 0.000 claims description 3
230000007831 electrophysiology Effects 0.000 claims description 3
125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 3
125000001041 indolyl group Chemical group 0.000 claims description 3
125000000842 isoxazolyl group Chemical group 0.000 claims description 3
239000006187 pill Substances 0.000 claims description 3
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 3
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
208000031019 skin pigmentation disease Diseases 0.000 claims description 3
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 3
DVQDOPNULJJRIC-UHFFFAOYSA-N 3-(4-chloro-3-methoxyphenyl)-8-[(4-methoxy-2,3-dimethylphenyl)methyl]-8-azabicyclo[3.2.1]octan-3-ol Chemical compound CC1=C(C)C(OC)=CC=C1CN1C2CCC1CC(O)(C=1C=C(OC)C(Cl)=CC=1)C2 DVQDOPNULJJRIC-UHFFFAOYSA-N 0.000 claims description 2
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
HREZEXWGSYQUAI-UHFFFAOYSA-N bicyclo[3.2.1]octan-3-ol Chemical compound C1C(O)CC2CCC1C2 HREZEXWGSYQUAI-UHFFFAOYSA-N 0.000 claims description 2
125000001309 chloro group Chemical group Cl* 0.000 claims description 2
125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 claims description 2
125000005879 dioxolanyl group Chemical group 0.000 claims description 2
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
230000005764 inhibitory process Effects 0.000 claims description 2
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 2
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 claims description 2
125000002098 pyridazinyl group Chemical group 0.000 claims description 2
125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims description 2
125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
102000006953 melanin-concentrating hormone receptor activity proteins Human genes 0.000 claims 19
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 5
125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 3
125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
210000004958 brain cell Anatomy 0.000 claims 2
ORZWRTZUWQCYGG-UHFFFAOYSA-N 1-[3-[4-[[3-(4-chloro-3-methoxyphenyl)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl]methyl]-2,3-dimethylphenoxy]propyl]pyrrolidin-2-one Chemical compound C1=C(Cl)C(OC)=CC(C2(O)CC3CCC(N3CC=3C(=C(C)C(OCCCN4C(CCC4)=O)=CC=3)C)C2)=C1 ORZWRTZUWQCYGG-UHFFFAOYSA-N 0.000 claims 1
LFOMHUZVEASICJ-UHFFFAOYSA-N 3-(4-chloro-3-methoxyphenyl)-8-[1-(4-methoxy-2,3-dimethylphenyl)ethyl]-8-azabicyclo[3.2.1]octan-3-ol Chemical compound CC1=C(C)C(OC)=CC=C1C(C)N1C2CCC1CC(O)(C=1C=C(OC)C(Cl)=CC=1)C2 LFOMHUZVEASICJ-UHFFFAOYSA-N 0.000 claims 1
NLZODKPFDPKYFG-UHFFFAOYSA-N 3-(4-chloro-3-methoxyphenyl)-8-[[4-(3-methoxypropoxy)-2,3-dimethylphenyl]methyl]-8-azabicyclo[3.2.1]octan-3-ol Chemical compound CC1=C(C)C(OCCCOC)=CC=C1CN1C2CCC1CC(O)(C=1C=C(OC)C(Cl)=CC=1)C2 NLZODKPFDPKYFG-UHFFFAOYSA-N 0.000 claims 1
DTMOQJMLEYWKTL-UHFFFAOYSA-N COC1=C(C(=C(C=C1)C(C)N1C2CC(CC1CC2)(O)C2=CC=C(C=C2)C(F)(F)F)C)C Chemical compound COC1=C(C(=C(C=C1)C(C)N1C2CC(CC1CC2)(O)C2=CC=C(C=C2)C(F)(F)F)C)C DTMOQJMLEYWKTL-UHFFFAOYSA-N 0.000 claims 1
QXFCGGMXMBAUHB-UHFFFAOYSA-N COC1=C(C(=C(C=C1)C(C)N1C2CC(CC1CC2)C(=O)C2=CC=C(C=C2)C(F)(F)F)C)C Chemical compound COC1=C(C(=C(C=C1)C(C)N1C2CC(CC1CC2)C(=O)C2=CC=C(C=C2)C(F)(F)F)C)C QXFCGGMXMBAUHB-UHFFFAOYSA-N 0.000 claims 1
102400001132 Melanin-concentrating hormone Human genes 0.000 description 64
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 31
238000012360 testing method Methods 0.000 description 30
239000000243 solution Substances 0.000 description 29
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
229940075993 receptor modulator Drugs 0.000 description 26
239000000556 agonist Substances 0.000 description 25
239000005557 antagonist Substances 0.000 description 25
125000004432 carbon atom Chemical group C* 0.000 description 25
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 22
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
238000006243 chemical reaction Methods 0.000 description 20
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 19
238000002360 preparation method Methods 0.000 description 19
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
229910052799 carbon Inorganic materials 0.000 description 18
239000003814 drug Substances 0.000 description 18
239000012528 membrane Substances 0.000 description 18
210000004379 membrane Anatomy 0.000 description 18
101000581402 Homo sapiens Melanin-concentrating hormone receptor 1 Proteins 0.000 description 17
239000000460 chlorine Substances 0.000 description 16
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 15
102100027375 Melanin-concentrating hormone receptor 1 Human genes 0.000 description 15
239000000523 sample Substances 0.000 description 15
229910052717 sulfur Inorganic materials 0.000 description 15
239000011734 sodium Substances 0.000 description 14
235000019441 ethanol Nutrition 0.000 description 13
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 13
102000004169 proteins and genes Human genes 0.000 description 13
108090000623 proteins and genes Proteins 0.000 description 13
230000002829 reductive effect Effects 0.000 description 13
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
241000700159 Rattus Species 0.000 description 12
125000002252 acyl group Chemical group 0.000 description 12
125000003342 alkenyl group Chemical group 0.000 description 12
229910052760 oxygen Inorganic materials 0.000 description 12
238000000159 protein binding assay Methods 0.000 description 12
229920006395 saturated elastomer Polymers 0.000 description 12
239000000725 suspension Substances 0.000 description 12
229940124597 therapeutic agent Drugs 0.000 description 12
125000000304 alkynyl group Chemical group 0.000 description 11
239000000872 buffer Substances 0.000 description 11
239000003921 oil Substances 0.000 description 11
235000019198 oils Nutrition 0.000 description 11
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
238000001727 in vivo Methods 0.000 description 10
238000003786 synthesis reaction Methods 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
239000002253 acid Substances 0.000 description 9
125000004429 atom Chemical group 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 9
239000012267 brine Substances 0.000 description 9
235000019439 ethyl acetate Nutrition 0.000 description 9
125000005842 heteroatom Chemical group 0.000 description 9
210000004185 liver Anatomy 0.000 description 9
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
230000004044 response Effects 0.000 description 9
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
239000007787 solid Substances 0.000 description 9
239000002904 solvent Substances 0.000 description 9
229940124802 CB1 antagonist Drugs 0.000 description 8
241000282412 Homo Species 0.000 description 8
238000005481 NMR spectroscopy Methods 0.000 description 8
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
239000004480 active ingredient Substances 0.000 description 8
125000004453 alkoxycarbonyl group Chemical group 0.000 description 8
239000012148 binding buffer Substances 0.000 description 8
238000001514 detection method Methods 0.000 description 8
229960004756 ethanol Drugs 0.000 description 8
238000009472 formulation Methods 0.000 description 8
239000008188 pellet Substances 0.000 description 8
239000003755 preservative agent Substances 0.000 description 8
206010006550 Bulimia nervosa Diseases 0.000 description 7
241000282472 Canis lupus familiaris Species 0.000 description 7
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
229930006000 Sucrose Natural products 0.000 description 7
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
239000000839 emulsion Substances 0.000 description 7
238000011534 incubation Methods 0.000 description 7
230000003834 intracellular effect Effects 0.000 description 7
150000004885 piperazines Chemical class 0.000 description 7
239000000843 powder Substances 0.000 description 7
235000010356 sorbitol Nutrition 0.000 description 7
239000000600 sorbitol Substances 0.000 description 7
239000005720 sucrose Substances 0.000 description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
101150104680 MCH1 gene Proteins 0.000 description 6
102100027373 Melanin-concentrating hormone receptor 2 Human genes 0.000 description 6
101100382379 Rattus norvegicus Cap1 gene Proteins 0.000 description 6
108091006629 SLC13A2 Proteins 0.000 description 6
239000007983 Tris buffer Substances 0.000 description 6
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 6
125000004414 alkyl thio group Chemical group 0.000 description 6
210000004556 brain Anatomy 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
230000006870 function Effects 0.000 description 6
210000003016 hypothalamus Anatomy 0.000 description 6
125000005647 linker group Chemical group 0.000 description 6
210000001577 neostriatum Anatomy 0.000 description 6
230000007935 neutral effect Effects 0.000 description 6
230000009871 nonspecific binding Effects 0.000 description 6
239000001301 oxygen Substances 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
239000000018 receptor agonist Substances 0.000 description 6
229940044601 receptor agonist Drugs 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
125000004434 sulfur atom Chemical group 0.000 description 6
239000000375 suspending agent Substances 0.000 description 6
230000000699 topical effect Effects 0.000 description 6
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
229910052722 tritium Inorganic materials 0.000 description 6
239000000080 wetting agent Substances 0.000 description 6
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
241000282693 Cercopithecidae Species 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
101710089759 Melanin-concentrating hormone receptor 2 Proteins 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
239000013543 active substance Substances 0.000 description 5
125000003282 alkyl amino group Chemical group 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
125000003277 amino group Chemical group 0.000 description 5
239000002585 base Substances 0.000 description 5
230000037396 body weight Effects 0.000 description 5
239000011575 calcium Substances 0.000 description 5
229910052791 calcium Inorganic materials 0.000 description 5
239000001768 carboxy methyl cellulose Substances 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
238000002648 combination therapy Methods 0.000 description 5
230000007423 decrease Effects 0.000 description 5
235000014113 dietary fatty acids Nutrition 0.000 description 5
125000006182 dimethyl benzyl group Chemical group 0.000 description 5
239000000975 dye Substances 0.000 description 5
239000003623 enhancer Substances 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
239000000194 fatty acid Substances 0.000 description 5
229930195729 fatty acid Natural products 0.000 description 5
150000004665 fatty acids Chemical class 0.000 description 5
239000000796 flavoring agent Substances 0.000 description 5
235000013355 food flavoring agent Nutrition 0.000 description 5
235000011187 glycerol Nutrition 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
125000001188 haloalkyl group Chemical group 0.000 description 5
244000144972 livestock Species 0.000 description 5
239000000463 material Substances 0.000 description 5
239000002609 medium Substances 0.000 description 5
208000030159 metabolic disease Diseases 0.000 description 5
239000002480 mineral oil Substances 0.000 description 5
235000010446 mineral oil Nutrition 0.000 description 5
MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
231100000252 nontoxic Toxicity 0.000 description 5
230000003000 nontoxic effect Effects 0.000 description 5
239000012044 organic layer Substances 0.000 description 5
230000036961 partial effect Effects 0.000 description 5
239000000651 prodrug Substances 0.000 description 5
229940002612 prodrug Drugs 0.000 description 5
229940044551 receptor antagonist Drugs 0.000 description 5
239000002464 receptor antagonist Substances 0.000 description 5
238000001525 receptor binding assay Methods 0.000 description 5
230000009467 reduction Effects 0.000 description 5
238000006722 reduction reaction Methods 0.000 description 5
125000006413 ring segment Chemical group 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
239000011534 wash buffer Substances 0.000 description 5
208000016261 weight loss Diseases 0.000 description 5
230000004580 weight loss Effects 0.000 description 5
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
SYBWCISSKWWJGV-UHFFFAOYSA-N 3-(4-chloro-3-methoxyphenyl)-8-azabicyclo[3.2.1]octan-3-ol Chemical compound C1=C(Cl)C(OC)=CC(C2(O)CC3CCC(N3)C2)=C1 SYBWCISSKWWJGV-UHFFFAOYSA-N 0.000 description 4
230000002407 ATP formation Effects 0.000 description 4
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
241000282465 Canis Species 0.000 description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
101500028288 Homo sapiens Melanin-concentrating hormone Proteins 0.000 description 4
229930194542 Keto Natural products 0.000 description 4
229930195725 Mannitol Natural products 0.000 description 4
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
206010052005 Psychogenic erectile dysfunction Diseases 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
239000003963 antioxidant agent Substances 0.000 description 4
235000006708 antioxidants Nutrition 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000000969 carrier Substances 0.000 description 4
239000003086 colorant Substances 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
239000002270 dispersing agent Substances 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
229940079593 drug Drugs 0.000 description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
235000003599 food sweetener Nutrition 0.000 description 4
239000000499 gel Substances 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
125000000468 ketone group Chemical group 0.000 description 4
235000010445 lecithin Nutrition 0.000 description 4
239000000787 lecithin Substances 0.000 description 4
229940067606 lecithin Drugs 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000000594 mannitol Substances 0.000 description 4
235000010355 mannitol Nutrition 0.000 description 4
230000003228 microsomal effect Effects 0.000 description 4
210000001672 ovary Anatomy 0.000 description 4
230000002093 peripheral effect Effects 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
238000012746 preparative thin layer chromatography Methods 0.000 description 4
239000000047 product Substances 0.000 description 4
239000008159 sesame oil Substances 0.000 description 4
235000011803 sesame oil Nutrition 0.000 description 4
230000019491 signal transduction Effects 0.000 description 4
125000003003 spiro group Chemical group 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000000758 substrate Substances 0.000 description 4
239000003765 sweetening agent Substances 0.000 description 4
229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 4
239000003826 tablet Substances 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
230000001988 toxicity Effects 0.000 description 4
235000015112 vegetable and seed oil Nutrition 0.000 description 4
239000008158 vegetable oil Substances 0.000 description 4
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
HOZLOOPIXHWKCI-UHFFFAOYSA-N 2-chloro-n-methylacetamide Chemical compound CNC(=O)CCl HOZLOOPIXHWKCI-UHFFFAOYSA-N 0.000 description 3
102100031126 6-phosphogluconolactonase Human genes 0.000 description 3
108010029731 6-phosphogluconolactonase Proteins 0.000 description 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
239000005995 Aluminium silicate Substances 0.000 description 3
108010039627 Aprotinin Proteins 0.000 description 3
241000416162 Astragalus gummifer Species 0.000 description 3
238000009010 Bradford assay Methods 0.000 description 3
241000699802 Cricetulus griseus Species 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
241000282326 Felis catus Species 0.000 description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
235000019483 Peanut oil Nutrition 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
229920002873 Polyethylenimine Polymers 0.000 description 3
239000004743 Polypropylene Substances 0.000 description 3
241000283984 Rodentia Species 0.000 description 3
235000021355 Stearic acid Nutrition 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
229920001615 Tragacanth Polymers 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
125000004390 alkyl sulfonyl group Chemical group 0.000 description 3
235000012211 aluminium silicate Nutrition 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
229960004405 aprotinin Drugs 0.000 description 3
239000007900 aqueous suspension Substances 0.000 description 3
239000012131 assay buffer Substances 0.000 description 3
238000000376 autoradiography Methods 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
125000002837 carbocyclic group Chemical group 0.000 description 3
150000001721 carbon Chemical group 0.000 description 3
239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000000576 coating method Methods 0.000 description 3
239000003240 coconut oil Substances 0.000 description 3
235000019864 coconut oil Nutrition 0.000 description 3
239000007859 condensation product Substances 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
230000037213 diet Effects 0.000 description 3
229960001760 dimethyl sulfoxide Drugs 0.000 description 3
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 3
208000037765 diseases and disorders Diseases 0.000 description 3
239000003651 drinking water Substances 0.000 description 3
235000020188 drinking water Nutrition 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
239000003974 emollient agent Substances 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000011737 fluorine Substances 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
235000012631 food intake Nutrition 0.000 description 3
239000007789 gas Substances 0.000 description 3
239000008103 glucose Substances 0.000 description 3
230000036541 health Effects 0.000 description 3
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 3
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
210000001853 liver microsome Anatomy 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
238000004020 luminiscence type Methods 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
238000002156 mixing Methods 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
125000004433 nitrogen atom Chemical group N* 0.000 description 3
210000004940 nucleus Anatomy 0.000 description 3
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
239000004006 olive oil Substances 0.000 description 3
235000008390 olive oil Nutrition 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000000312 peanut oil Substances 0.000 description 3
230000035515 penetration Effects 0.000 description 3
229920001155 polypropylene Polymers 0.000 description 3
239000013641 positive control Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
235000013772 propylene glycol Nutrition 0.000 description 3
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
238000000746 purification Methods 0.000 description 3
JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
235000015424 sodium Nutrition 0.000 description 3
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
239000008107 starch Substances 0.000 description 3
239000008117 stearic acid Substances 0.000 description 3
239000011593 sulfur Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000010189 synthetic method Methods 0.000 description 3
239000000454 talc Substances 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
238000005406 washing Methods 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
KOPFEFZSAMLEHK-UHFFFAOYSA-N 1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1C=CNN=1 KOPFEFZSAMLEHK-UHFFFAOYSA-N 0.000 description 2
JACOAEATKHHHQS-UHFFFAOYSA-N 2-[4-[[3-(4-chloro-3-methoxyphenyl)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl]methyl]-2,3-dimethylphenoxy]-n-methylacetamide Chemical compound CC1=C(C)C(OCC(=O)NC)=CC=C1CN1C2CCC1CC(O)(C=1C=C(OC)C(Cl)=CC=1)C2 JACOAEATKHHHQS-UHFFFAOYSA-N 0.000 description 2
VLINVBMYFZRDCA-UHFFFAOYSA-N 3-(4-chloro-3-methoxyphenyl)-8-[[4-[3-(dimethylamino)propoxy]-2,3-dimethylphenyl]methyl]-8-azabicyclo[3.2.1]octan-3-ol Chemical compound C1=C(Cl)C(OC)=CC(C2(O)CC3CCC(N3CC=3C(=C(C)C(OCCCN(C)C)=CC=3)C)C2)=C1 VLINVBMYFZRDCA-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
235000006491 Acacia senegal Nutrition 0.000 description 2
KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical class CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
208000008811 Agoraphobia Diseases 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
108010001478 Bacitracin Proteins 0.000 description 2
108010017384 Blood Proteins Proteins 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 2
208000032841 Bulimia Diseases 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 2
108091006027 G proteins Proteins 0.000 description 2
102000030782 GTP binding Human genes 0.000 description 2
108091000058 GTP-Binding Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
206010019842 Hepatomegaly Diseases 0.000 description 2
229940127517 Hormone Receptor Modulators Drugs 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
241000282567 Macaca fascicularis Species 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
102100023724 Melanocortin receptor 4 Human genes 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
102000003797 Neuropeptides Human genes 0.000 description 2
108090000189 Neuropeptides Proteins 0.000 description 2
101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
ZPHBZEQOLSRPAK-UHFFFAOYSA-N Phosphoramidon Natural products C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O ZPHBZEQOLSRPAK-UHFFFAOYSA-N 0.000 description 2
208000012641 Pigmentation disease Diseases 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
206010047642 Vitiligo Diseases 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
208000012826 adjustment disease Diseases 0.000 description 2
230000007000 age related cognitive decline Effects 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
125000000278 alkyl amino alkyl group Chemical group 0.000 description 2
POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
125000004103 aminoalkyl group Chemical group 0.000 description 2
235000011114 ammonium hydroxide Nutrition 0.000 description 2
235000019789 appetite Nutrition 0.000 description 2
230000036528 appetite Effects 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
229960003071 bacitracin Drugs 0.000 description 2
229930184125 bacitracin Natural products 0.000 description 2
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
125000002619 bicyclic group Chemical group 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000008499 blood brain barrier function Effects 0.000 description 2
210000001218 blood-brain barrier Anatomy 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
235000010216 calcium carbonate Nutrition 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
108700010039 chimeric receptor Proteins 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
238000002784 cytotoxicity assay Methods 0.000 description 2
231100000263 cytotoxicity test Toxicity 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 2
229910052805 deuterium Inorganic materials 0.000 description 2
DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
238000007865 diluting Methods 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
230000029142 excretion Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
239000011888 foil Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
230000037406 food intake Effects 0.000 description 2
238000002825 functional assay Methods 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
239000008187 granular material Substances 0.000 description 2
150000004820 halides Chemical class 0.000 description 2
210000003494 hepatocyte Anatomy 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
210000001320 hippocampus Anatomy 0.000 description 2
238000000265 homogenisation Methods 0.000 description 2
239000011539 homogenization buffer Substances 0.000 description 2
239000003906 humectant Substances 0.000 description 2
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
125000002768 hydroxyalkyl group Chemical group 0.000 description 2
150000002460 imidazoles Chemical class 0.000 description 2
125000002883 imidazolyl group Chemical group 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
229940125425 inverse agonist Drugs 0.000 description 2
239000011630 iodine Substances 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
229960004592 isopropanol Drugs 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000002502 liposome Substances 0.000 description 2
229940057995 liquid paraffin Drugs 0.000 description 2
230000004807 localization Effects 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000003550 marker Substances 0.000 description 2
ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 2
102000047659 melanin-concentrating hormone Human genes 0.000 description 2
210000001259 mesencephalon Anatomy 0.000 description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
210000001589 microsome Anatomy 0.000 description 2
208000027061 mild cognitive impairment Diseases 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
239000000346 nonvolatile oil Substances 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
BWSDNRQVTFZQQD-AYVHNPTNSA-N phosphoramidon Chemical compound O([P@@](O)(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC=1[C]2C=CC=CC2=NC=1)C(O)=O)[C@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]1O BWSDNRQVTFZQQD-AYVHNPTNSA-N 0.000 description 2
108010072906 phosphoramidon Proteins 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
239000003380 propellant Substances 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
239000002287 radioligand Substances 0.000 description 2
230000001850 reproductive effect Effects 0.000 description 2
229960003015 rimonabant Drugs 0.000 description 2
238000010898 silica gel chromatography Methods 0.000 description 2
208000017520 skin disease Diseases 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
238000004611 spectroscopical analysis Methods 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000012289 standard assay Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000003860 storage Methods 0.000 description 2
208000023516 stroke disease Diseases 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000000829 suppository Substances 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
230000002463 transducing effect Effects 0.000 description 2
238000012384 transportation and delivery Methods 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
QQXLDOJGLXJCSE-KNVOCYPGSA-N tropinone Chemical compound C1C(=O)C[C@H]2CC[C@@H]1N2C QQXLDOJGLXJCSE-KNVOCYPGSA-N 0.000 description 2
239000002691 unilamellar liposome Substances 0.000 description 2
238000003828 vacuum filtration Methods 0.000 description 2
DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
LPUCHTNHUHOTRY-UHFFFAOYSA-N 1-(3-bicyclo[2.2.1]heptanyl)ethanamine Chemical compound C1CC2C(C(N)C)CC1C2 LPUCHTNHUHOTRY-UHFFFAOYSA-N 0.000 description 1
WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical group CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
BNYCHCAYYYRJSH-UHFFFAOYSA-N 1h-pyrazole-5-carboxamide Chemical class NC(=O)C1=CC=NN1 BNYCHCAYYYRJSH-UHFFFAOYSA-N 0.000 description 1
HDIFHQMREAYYJW-FMIVXFBMSA-N 2,3-dihydroxypropyl (e)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C\CCCCCCCC(=O)OCC(O)CO HDIFHQMREAYYJW-FMIVXFBMSA-N 0.000 description 1
WKAXDAMWMOBXMP-UHFFFAOYSA-N 2,3-diphenylpyridine Chemical class C1=CC=CC=C1C1=CC=CN=C1C1=CC=CC=C1 WKAXDAMWMOBXMP-UHFFFAOYSA-N 0.000 description 1
YANPAVHFFWLLEL-ICSRJNTNSA-N 2-(2-chlorophenyl)-1-(4-chlorophenyl)-n-[(1s,2s)-2-hydroxycyclohexyl]imidazole-4-carboxamide Chemical compound O[C@H]1CCCC[C@@H]1NC(=O)C1=CN(C=2C=CC(Cl)=CC=2)C(C=2C(=CC=CC=2)Cl)=N1 YANPAVHFFWLLEL-ICSRJNTNSA-N 0.000 description 1
FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
ACHARCXLWAWAIO-UHFFFAOYSA-N 2-[4-[[3-(4-chloro-3-methoxyphenyl)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl]methyl]-2,3-dimethylphenoxy]-n,n-dimethylacetamide Chemical compound C1=C(Cl)C(OC)=CC(C2(O)CC3CCC(N3CC=3C(=C(C)C(OCC(=O)N(C)C)=CC=3)C)C2)=C1 ACHARCXLWAWAIO-UHFFFAOYSA-N 0.000 description 1
125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
XBPPLECAZBTMMK-UHFFFAOYSA-N 2-chloro-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CCl XBPPLECAZBTMMK-UHFFFAOYSA-N 0.000 description 1
ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
OJIBJRXMHVZPLV-UHFFFAOYSA-N 2-methylpropyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(C)C OJIBJRXMHVZPLV-UHFFFAOYSA-N 0.000 description 1
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
JZURFBPELHSHKR-UHFFFAOYSA-N 3-(4-chloro-3-methoxyphenyl)-8-[[4-(2-methoxyethoxy)-2,3-dimethylphenyl]methyl]-8-azabicyclo[3.2.1]octan-3-ol Chemical compound CC1=C(C)C(OCCOC)=CC=C1CN1C2CCC1CC(O)(C=1C=C(OC)C(Cl)=CC=1)C2 JZURFBPELHSHKR-UHFFFAOYSA-N 0.000 description 1
OOZXPKNEERPKLG-UHFFFAOYSA-N 3-(4-chloro-3-methoxyphenyl)-8-[[4-(3-hydroxypropoxy)-2,3-dimethylphenyl]methyl]-8-azabicyclo[3.2.1]octan-3-ol Chemical compound C1=C(Cl)C(OC)=CC(C2(O)CC3CCC(N3CC=3C(=C(C)C(OCCCO)=CC=3)C)C2)=C1 OOZXPKNEERPKLG-UHFFFAOYSA-N 0.000 description 1
125000005917 3-methylpentyl group Chemical group 0.000 description 1
125000005925 3-methylpentyloxy group Chemical group 0.000 description 1
UAMVKOTWSHJOSY-UHFFFAOYSA-N 4-bromo-1-chloro-2-methoxybenzene Chemical compound COC1=CC(Br)=CC=C1Cl UAMVKOTWSHJOSY-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
MAFDJCNDRCNZFM-UHFFFAOYSA-N 4-methoxy-2,3-dimethylbenzaldehyde Chemical compound COC1=CC=C(C=O)C(C)=C1C MAFDJCNDRCNZFM-UHFFFAOYSA-N 0.000 description 1
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
AMEMLELAMQEAIA-UHFFFAOYSA-N 6-(tert-butyl)thieno[3,2-d]pyrimidin-4(3H)-one Chemical compound N1C=NC(=O)C2=C1C=C(C(C)(C)C)S2 AMEMLELAMQEAIA-UHFFFAOYSA-N 0.000 description 1
125000001960 7 membered carbocyclic group Chemical group 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
244000144927 Aloe barbadensis Species 0.000 description 1
235000002961 Aloe barbadensis Nutrition 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010002758 Anticipatory anxiety Diseases 0.000 description 1
102100033367 Appetite-regulating hormone Human genes 0.000 description 1
101710111255 Appetite-regulating hormone Proteins 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
101150041968 CDC13 gene Proteins 0.000 description 1
229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
206010007269 Carcinogenicity Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
101710178035 Chorismate synthase 2 Proteins 0.000 description 1
208000028698 Cognitive impairment Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
101710152694 Cysteine synthase 2 Proteins 0.000 description 1
108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 1
108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 1
108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
102100026533 Cytochrome P450 1A2 Human genes 0.000 description 1
102100036194 Cytochrome P450 2A6 Human genes 0.000 description 1
102100029363 Cytochrome P450 2C19 Human genes 0.000 description 1
102100029358 Cytochrome P450 2C9 Human genes 0.000 description 1
102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
102100024889 Cytochrome P450 2E1 Human genes 0.000 description 1
102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 1
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
102000034353 G alpha subunit Human genes 0.000 description 1
108091006099 G alpha subunit Proteins 0.000 description 1
102400001370 Galanin Human genes 0.000 description 1
101800002068 Galanin Proteins 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
101000875170 Homo sapiens Cytochrome P450 2A6 Proteins 0.000 description 1
101000581408 Homo sapiens Melanin-concentrating hormone receptor 2 Proteins 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010063743 Hypophagia Diseases 0.000 description 1
206010065390 Inflammatory pain Diseases 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
102000016267 Leptin Human genes 0.000 description 1
108010092277 Leptin Proteins 0.000 description 1
229940122942 Leptin receptor agonist Drugs 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
244000246386 Mentha pulegium Species 0.000 description 1
235000016257 Mentha pulegium Nutrition 0.000 description 1
235000004357 Mentha x piperita Nutrition 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
239000004909 Moisturizer Substances 0.000 description 1
208000019022 Mood disease Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 1
229910017974 NH40H Inorganic materials 0.000 description 1
241000772415 Neovison vison Species 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
102000002512 Orexin Human genes 0.000 description 1
102000016978 Orphan receptors Human genes 0.000 description 1
108070000031 Orphan receptors Proteins 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
108010081690 Pertussis Toxin Proteins 0.000 description 1
206010034912 Phobia Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
208000000810 Separation Anxiety Diseases 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
206010041250 Social phobia Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 1
208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
206010046543 Urinary incontinence Diseases 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
208000021017 Weight Gain Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical group [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
229940048299 acetylated lanolin alcohols Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000011149 active material Substances 0.000 description 1
208000026345 acute stress disease Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
230000008484 agonism Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000002009 alkene group Chemical group 0.000 description 1
125000002355 alkine group Chemical group 0.000 description 1
125000005431 alkyl carboxamide group Chemical group 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
229960000458 allantoin Drugs 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000003281 allosteric effect Effects 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
235000011399 aloe vera Nutrition 0.000 description 1
229910000323 aluminium silicate Inorganic materials 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
210000004727 amygdala Anatomy 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
150000004792 aryl magnesium halides Chemical class 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
238000011914 asymmetric synthesis Methods 0.000 description 1
125000003725 azepanyl group Chemical group 0.000 description 1
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
150000001539 azetidines Chemical class 0.000 description 1
125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
150000003935 benzaldehydes Chemical class 0.000 description 1
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000001743 benzylic group Chemical group 0.000 description 1
102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
230000006583 body weight regulation Effects 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001273 butane Substances 0.000 description 1
DHAZIUXMHRHVMP-UHFFFAOYSA-N butyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCC DHAZIUXMHRHVMP-UHFFFAOYSA-N 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
229910000024 caesium carbonate Inorganic materials 0.000 description 1
QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 1
229950011318 cannabidiol Drugs 0.000 description 1
ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 1
239000003536 cannabinoid receptor antagonist Substances 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical group C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
150000003857 carboxamides Chemical class 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
231100000260 carcinogenicity Toxicity 0.000 description 1
230000007670 carcinogenicity Effects 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
229960001777 castor oil Drugs 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
238000003320 cell separation method Methods 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
229940074979 cetyl palmitate Drugs 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000007810 chemical reaction solvent Substances 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
238000004296 chiral HPLC Methods 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
231100000505 clastogenic Toxicity 0.000 description 1
230000003541 clastogenic effect Effects 0.000 description 1
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
229960004170 clozapine Drugs 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000007278 cognition impairment Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
229940125810 compound 20 Drugs 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940041967 corticotropin-releasing hormone Drugs 0.000 description 1
KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
150000001907 coumarones Chemical class 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
208000026725 cyclothymic disease Diseases 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
229960004597 dexfenfluramine Drugs 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical class O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940028356 diethylene glycol monobutyl ether Drugs 0.000 description 1
XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 1
239000004205 dimethyl polysiloxane Substances 0.000 description 1
235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
OQKHVXFOYFBMDJ-OOLZXIKUSA-L disodium;3-(1h-indol-3-yl)-2-[[4-methyl-2-[[oxido-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyphosphoryl]amino]pentanoyl]amino]propanoate Chemical compound [Na+].[Na+].C=1NC2=CC=CC=C2C=1CC(C([O-])=O)NC(=O)C(CC(C)C)NP([O-])(=O)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O OQKHVXFOYFBMDJ-OOLZXIKUSA-L 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
208000024732 dysthymic disease Diseases 0.000 description 1
235000005686 eating Nutrition 0.000 description 1
230000007937 eating Effects 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
238000002565 electrocardiography Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
NOAYBWMMVRQJSW-UHFFFAOYSA-N ethyl 3-(4-chloro-3-methoxyphenyl)-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound CCOC(=O)N1C(C2)CCC1CC2(O)C1=CC=C(Cl)C(OC)=C1 NOAYBWMMVRQJSW-UHFFFAOYSA-N 0.000 description 1
ANEJUHJDPGTVIO-UHFFFAOYSA-N ethyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound C1C(=O)CC2CCC1N2C(=O)OCC ANEJUHJDPGTVIO-UHFFFAOYSA-N 0.000 description 1
229960004667 ethyl cellulose Drugs 0.000 description 1
235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
239000001761 ethyl methyl cellulose Substances 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
229940093476 ethylene glycol Drugs 0.000 description 1
NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical group CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
230000005284 excitation Effects 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000008369 fruit flavor Substances 0.000 description 1
229910000286 fullers earth Inorganic materials 0.000 description 1
229910021485 fumed silica Inorganic materials 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
RCFDIXKVOHJQPP-UHFFFAOYSA-N furo[2,3-b]pyridine Chemical class C1=CN=C2OC=CC2=C1 RCFDIXKVOHJQPP-UHFFFAOYSA-N 0.000 description 1
230000004927 fusion Effects 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
229960005150 glycerol Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
150000004795 grignard reagents Chemical class 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003324 growth hormone secretagogue Substances 0.000 description 1
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
230000003400 hallucinatory effect Effects 0.000 description 1
125000004438 haloalkoxy group Chemical group 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229940100463 hexyl laurate Drugs 0.000 description 1
235000001050 hortel pimenta Nutrition 0.000 description 1
102000047277 human MCHR1 Human genes 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
201000001881 impotence Diseases 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000004068 intracellular signaling Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000001282 iso-butane Substances 0.000 description 1
235000013847 iso-butane Nutrition 0.000 description 1
229940078545 isocetyl stearate Drugs 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229940093629 isopropyl isostearate Drugs 0.000 description 1
229940033357 isopropyl laurate Drugs 0.000 description 1
229940074928 isopropyl myristate Drugs 0.000 description 1
XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
229940075495 isopropyl palmitate Drugs 0.000 description 1
229940089456 isopropyl stearate Drugs 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
229940039781 leptin Drugs 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
239000006210 lotion Substances 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000013507 mapping Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
229940041616 menthol Drugs 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000037323 metabolic rate Effects 0.000 description 1
LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229940073584 methylene chloride Drugs 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
239000008267 milk Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
244000309715 mini pig Species 0.000 description 1
239000007758 minimum essential medium Substances 0.000 description 1
230000001333 moisturizer Effects 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
230000036651 mood Effects 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
229940078812 myristyl myristate Drugs 0.000 description 1
229940078555 myristyl propionate Drugs 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
239000013642 negative control Substances 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
239000001272 nitrous oxide Substances 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
OXGBCSQEKCRCHN-UHFFFAOYSA-N octadecan-2-ol Chemical compound CCCCCCCCCCCCCCCCC(C)O OXGBCSQEKCRCHN-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
229940055577 oleyl alcohol Drugs 0.000 description 1
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
210000001010 olfactory tubercle Anatomy 0.000 description 1
229940054534 ophthalmic solution Drugs 0.000 description 1
239000002997 ophthalmic solution Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
108060005714 orexin Proteins 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
125000002524 organometallic group Chemical group 0.000 description 1
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
JCGNDDUYTRNOFT-UHFFFAOYSA-N oxolane-2,4-dione Chemical compound O=C1COC(=O)C1 JCGNDDUYTRNOFT-UHFFFAOYSA-N 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
235000019629 palatability Nutrition 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
208000019906 panic disease Diseases 0.000 description 1
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000007967 peppermint flavor Substances 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
238000002600 positron emission tomography Methods 0.000 description 1
208000028173 post-traumatic stress disease Diseases 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
XEIOPEQGDSYOIH-MURFETPASA-N propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(C)C XEIOPEQGDSYOIH-MURFETPASA-N 0.000 description 1
ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
239000001294 propane Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
210000004129 prosencephalon Anatomy 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
150000003216 pyrazines Chemical class 0.000 description 1
150000003217 pyrazoles Chemical class 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
238000003653 radioligand binding assay Methods 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
210000001202 rhombencephalon Anatomy 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
208000025874 separation anxiety disease Diseases 0.000 description 1
239000003478 serotonin 5-HT2 receptor agonist Substances 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
229960004425 sibutramine Drugs 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
231100000188 sister chromatid exchange Toxicity 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
239000012453 solvate Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
201000001716 specific phobia Diseases 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
210000003523 substantia nigra Anatomy 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
210000002820 sympathetic nervous system Anatomy 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
210000001138 tear Anatomy 0.000 description 1
MENILFUADYEXNU-DTORHVGOSA-N tert-butyl (1r,5s)-3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound C1C(=O)C[C@H]2CC[C@@H]1N2C(=O)OC(C)(C)C MENILFUADYEXNU-DTORHVGOSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
125000005207 tetraalkylammonium group Chemical group 0.000 description 1
BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
YRZGMTHQPGNLEK-UHFFFAOYSA-N tetradecyl propionate Chemical compound CCCCCCCCCCCCCCOC(=O)CC YRZGMTHQPGNLEK-UHFFFAOYSA-N 0.000 description 1
DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
125000006337 tetrafluoro ethyl group Chemical group 0.000 description 1
WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
210000001103 thalamus Anatomy 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
230000006032 tissue transformation Effects 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000003325 tomography Methods 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
125000001874 trioxidanyl group Chemical group [*]OOO[H] 0.000 description 1
150000008303 tropinone derivatives Chemical class 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
239000013598 vector Substances 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
230000037221 weight management Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Obesity (AREA)
Dermatology (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)

AU2005296124A 2004-10-13 2005-10-04 Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor Abandoned AU2005296124A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US61829204P	2004-10-13	2004-10-13
US60/618,292		2004-10-13
PCT/US2005/035457 WO2006044174A2 (fr)	2004-10-13	2005-10-04	Composes de 8-azabicyclo[3.2.1]octane a substitution aryle comme ligands du recepteur de l'hormone de concentration de la melanine

Publications (1)

Publication Number	Publication Date
AU2005296124A1 true AU2005296124A1 (en)	2006-04-27

Family

ID=36088256

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2005296124A Abandoned AU2005296124A1 (en)	2004-10-13	2005-10-04	Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor

Country Status (5)

Country	Link
EP (1)	EP1809626A2 (fr)
JP (1)	JP2008515972A (fr)
AU (1)	AU2005296124A1 (fr)
CA (1)	CA2581745A1 (fr)
WO (1)	WO2006044174A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2911874B1 (fr) *	2007-01-25	2009-03-06	Sanofi Aventis Sa	Derives d'urees de tropane, leur preparation et leur application en therapeutique
CA2666193A1 (fr)	2006-08-08	2008-02-14	Sanofi-Aventis	Imidazolidin-2,4-dione arylaminoaryl-alkyl-substituee, son procede de fabrication, medicament contenant ce compose et son utilisation
CA2678577A1 (fr)	2007-02-26	2008-09-04	Vitae Pharmaceuticals, Inc.	Inhibiteurs d'uree et de carbamate de 11b-hydroxysteroide deshydrogenase 1 cycliques
AR069207A1 (es)	2007-11-07	2010-01-06	Vitae Pharmaceuticals Inc	Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
JP5769970B2 (ja)	2007-11-16	2015-08-26	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ベンゾモルファン及び関連骨格のアリール−及びヘテロアリールカルボニル誘導体、かかる化合物を含有する医薬及びこれらの使用
US8440658B2 (en)	2007-12-11	2013-05-14	Vitae Pharmaceuticals, Inc.	Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
US8138178B2 (en)	2008-05-01	2012-03-20	Vitae Pharmaceuticals, Inc.	Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2009137270A2 (fr) *	2008-05-09	2009-11-12	H. Lundbeck A/S	Dérivés d'azétidine
EP2288596B1 (fr)	2008-05-13	2016-11-30	Boehringer Ingelheim International GmbH	Dérivés d acide carboxylique alicyclique de benzomorphanes et échafaudages afférents, médicaments contenant ces composés, et utilisation de ceux-ci
EP2310372B1 (fr)	2008-07-09	2012-05-23	Sanofi	Composés hétérocycliques, leur procédé de préparation, médicaments les contenant et leur utilisation
CN102159572A (zh) *	2008-07-16	2011-08-17	先灵公司	双环杂环衍生物及其作为gpr 119调节剂的用途
US8114868B2 (en)	2008-07-25	2012-02-14	Boehringer Ingelheim International Gmbh	Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
WO2010010157A2 (fr)	2008-07-25	2010-01-28	Boehringer Ingelheim International Gmbh	Inhibiteurs de la 11 bêta-hydroxystéroïde déshydrogénase 1
CA2735204C (fr) *	2008-08-25	2017-06-20	Boehringer Ingelheim International Gmbh	Derives aryle et heteroarylcarbonyle de nortropanes substitues, medicaments contenant de tels composes et leurs applications
WO2010046445A2 (fr)	2008-10-23	2010-04-29	Boehringer Ingelheim International Gmbh	Dérivées d’urée de nortropanes substitués, médicaments contenant de tels composés et leur utilisation
WO2010068601A1 (fr)	2008-12-08	2010-06-17	Sanofi-Aventis	Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
WO2010089303A1 (fr)	2009-02-04	2010-08-12	Boehringer Ingelheim International Gmbh	Inhibiteurs cycliques de la 11β-hydroxystéroïde déshydrogénase de type 1
UA109255C2 (ru)	2009-04-30	2015-08-10	Берінгер Інгельхайм Інтернешнл Гмбх	Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
JP5670440B2 (ja)	2009-06-02	2015-02-18	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
WO2011011123A1 (fr)	2009-06-11	2011-01-27	Vitae Pharmaceuticals, Inc.	Inhibiteurs cycliques de la 11-bêta-hydroxystéroïde déshydrogénase 1 basée sur la structure 1,3-oxazinan-2-one
WO2011002910A1 (fr)	2009-07-01	2011-01-06	Vitae Pharmaceuticals, Inc.	Inhibiteurs cycliques de la 11-bêta-hydroxystéroïde déshydrogénase 1
US8785608B2 (en)	2009-08-26	2014-07-22	Sanofi	Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
UY33001A (es)	2009-11-06	2011-05-31	Boehringer Ingelheim Int	Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
US8933072B2 (en)	2010-06-16	2015-01-13	Vitae Pharmaceuticals, Inc.	Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
JP5813106B2 (ja)	2010-06-25	2015-11-17	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	代謝障害の処置のための１１−β−ＨＳＤ１のインヒビターとしてのアザスピロヘキサノン
KR20130137628A (ko)	2010-11-02	2013-12-17	베링거 인겔하임 인터내셔날 게엠베하	대사 장애를 치료하기 위한 약제학적 병용물
TWI537258B (zh)	2010-11-05	2016-06-11	百靈佳殷格翰國際股份有限公司	六氫茚并吡啶及八氫苯并喹啉之芳基－及雜環芳基羰基衍生物
WO2012120053A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
US8901114B2 (en)	2011-03-08	2014-12-02	Sanofi	Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8710050B2 (en)	2011-03-08	2014-04-29	Sanofi	Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120050A1 (fr)	2011-03-08	2012-09-13	Sanofi	Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, médicaments contenant ces composés et leur utilisation
EP2683701B1 (fr)	2011-03-08	2014-12-24	Sanofi	Dérivés d'oxathiazine substitués par des groupes de benzyle-méthyles ou d'hétéro-méthyles, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
EP2683703B1 (fr)	2011-03-08	2015-05-27	Sanofi	Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120051A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
US8871758B2 (en)	2011-03-08	2014-10-28	Sanofi	Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2013025664A1 (fr)	2011-08-17	2013-02-21	Boehringer Ingelheim International Gmbh	Dérivés d'indénopyridine
MX2019000536A (es)	2016-07-14	2019-04-01	Pfizer	Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1.
HRP20230502T1 (hr)	2017-10-27	2023-09-15	Boehringer Ingelheim International Gmbh	Inhibitori trpc6
MX2023001818A (es)	2020-08-13	2023-03-13	Boehringer Ingelheim Int	Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia.
KR20230088761A (ko)	2020-10-13	2023-06-20	베링거 인겔하임 인터내셔날 게엠베하	재가공하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002004433A2 (fr) *	2000-07-06	2002-01-17	Neurogen Corporation	Ligands de recepteur d'hormone a concentration de melanine
IL158941A0 (en) *	2001-05-22	2004-05-12	Neurogen Corp	Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues

2005
- 2005-10-04 EP EP05812516A patent/EP1809626A2/fr not_active Withdrawn
- 2005-10-04 WO PCT/US2005/035457 patent/WO2006044174A2/fr active Application Filing
- 2005-10-04 AU AU2005296124A patent/AU2005296124A1/en not_active Abandoned
- 2005-10-04 JP JP2007536725A patent/JP2008515972A/ja active Pending
- 2005-10-04 CA CA002581745A patent/CA2581745A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
CA2581745A1 (fr)	2006-04-27
EP1809626A2 (fr)	2007-07-25
WO2006044174A3 (fr)	2006-06-08
WO2006044174A9 (fr)	2006-07-20
JP2008515972A (ja)	2008-05-15
WO2006044174A2 (fr)	2006-04-27

Publication	Publication Date	Title
AU2005296124A1 (en)	2006-04-27	Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor
US20070249616A1 (en)	2007-10-25	Substituted 1-Benzyl-4-Substituted Piperazine Analogues
US6476038B1 (en)	2002-11-05	Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
US6815438B2 (en)	2004-11-09	Heteroaryl-diazabicycloalkanes
AU774867B2 (en)	2004-07-08	Heteroaryl diazabicycloalkanes, their preparation and use
US20060009456A1 (en)	2006-01-12	Aryl-substituted piperazine derivatives
US6680328B2 (en)	2004-01-20	8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives
US20090075983A1 (en)	2009-03-19	Novel Diazabicycloalkane Derivatives and Their Medical Use
EP1175416B1 (fr)	2003-07-16	Heteroaryl diazacycloalkanes, leur preparation et utilisation
WO2006015279A1 (fr)	2006-02-09	Composés de diamine hétérocyclique comme liants du récepteur d'hormone concentrant de la mélamine, utile pour le traitement de l'obésité, du diabète et des troubles sexuels et de l'alimentation
EP1465888A2 (fr)	2004-10-13	Ligands recepteurs de l'hormone de concentration de la melanine: analogues de benzoimidazole substitue
JP2003137872A (ja)	2003-05-14	置換２−シクロヘキシル−４−フェニル−１ｈ−イミダゾール誘導体
US20050239791A1 (en)	2005-10-27	Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues
JP2005516901A (ja)	2005-06-09	１Ｈ−ピロロ［３，２−ｂ］ピリジン−３−カルボン酸アミド化合物
US20080161344A1 (en)	2008-07-03	Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues

Legal Events

Date	Code	Title	Description
2009-10-22	MK1	Application lapsed section 142(2)(a) - no request for examination in relevant period